Brought to you by Applied Clinical Trials, The Clinical Data Disclosure and Transparency Resource Community is the go-to web destination for comprehensive data disclosure and transparency content.
Citeline Data Shows Higher Rate of Transparency Commitment
Sept. 10, 2014
TransCelerate Issues its CSR Redaction Approach for Data Sharing
Sept. 3, 2014
ECGCP Warns About Risks of Overprotecting Data
Aug. 1, 2014
ESMO's Concerns Over Data Protection and Research
July 25, 2014
Catching Up with Data Protection
July 21, 2014
EMA Delays Decision on Clinical Trial Data Until October
July 10, 2014
Pharma Improves Care by Sharing Clinical Trial Data
June 17, 2014
Privacy Analytics Launches Transparency Solution
June 18, 2014
Clinical Data Disclosure and Transparency
January 28-29, 2015 | Philadelphia, Pennsylvania
CBI’s successful inaugural event focusing on Clinical Data Disclosure and Transparency is back for its second year! This conference is the biggest of its kind and brings together high level executives to discuss and disseminate aspects of required data disclosure in a time of industry reform. Facing heightened pressure from the EMA, NIH, EFPIA, PhRMA and ICMJE to disclose clinical trial results and be transparent about all clinical trial data, this program focuses on the implications of and approaches being taken for data sharing, ensuring compliance with regulations, navigating disclosure requirements and releasing patient-level data.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.